Introduction
Shwachman-Diamond syndrome (SDS) is an autosomal recessive disorder (OMIM 260400), characterized by exocrine pancreatic insufficiency, skeletal abnormalities and bone marrow (BM) dysfunction, with a risk, as high as 30%, to develop myelodysplastic syndrome and/or acute myeloid leukaemia (MDS/AML). 1 The SBDS gene (OMIM 607744) is localized on chromosome 7 at the band q11 and mutations of this gene are found in 90% of patients. 2 Clonal chromosome anomalies are often found in the BM of SDS patients, often involving chromosomes 7 and 20, the most frequent being an isochromosome for the long arms of chromosome 7, i(7)(q10), and a deletion of the long arms of a 20, del(20)(q11). Recently, Shimamura 3 reviewed available evidence that patients with the i(7)(q10) should be considered as a separate group in terms of prognosis, as, in comparison to patients with different chromosome 7 anomalies, such as monosomy or deletion of the long arms, they have a lower risk of MDS/AML.
Most SDS patients carry at least one of the two most common mutations of the SBDS gene, in exon 2: c.183_184TA4CT and c.258 þ 2T4C; the first one introduces an in-frame stop codon (p.K62X), whereas the second one disrupts the donor splice site of intron 2 and results in a truncated protein. 2 Other rarer mutations were recently reviewed by Costa and Santos. 4 The SBDS gene, highly conserved throughout evolution, encodes a 250 amino-acid protein with no homology to other proteins of known function. This protein was shown to be relevant for ribosome biogenesis and, more recently, also for stabilization of the mitotic spindle. 5 A reduced but detectable quantity of the SBDS protein was shown to be present in fibroblasts of two SDS patients, this finding suggesting that the mutation found in these two cases, namely c.258 þ 2T4C, may lead to the presence of a small amount of alternatively spliced SBDS mRNA, encoding a functional protein. 6 Recently, Nicolis et al. 7 demonstrated that wild-type (wt) mRNA can be found in patients carrying this mutation.
To evaluate whether the mutations of the SBDS gene carried by i(7)(q10) have different roles in promoting the development of MDS/AML, we investigated the parental origin of the i(7)(q10) in the BM of eight patients, and, as all of them were compound heterozygotes for SBDS mutations, we inferred from the result which mutation was present in double dose in the isochromosome.
Material and methods
We retrospectively selected a cohort of eight SDS patients in whom: (i) the clinical diagnosis was confirmed by mutation analysis and (ii) the cytogenetic studies demonstrated the presence of i(7)(q10) in 20-100% mitoses from BM. Clinical characteristics, as well as essential data on cytogenetics and follow-up, are detailed in Table 1 . No patient ever showed signs of overt transformation into MDS/AML, including those with the longest follow-up (nos 1-3 and 5). All patients were compound heterozygotes with the c.258 þ 2T4C mutation; the second mutation was either the c.183_184TA4CT or the c.183_184TA4CT þ 258 þ 2T4C (Table 2) . Some data on cases 1-3 have been previously reported by Maserati et al., 8, 9 (unique patient number, UPN1) and Porta et al. 10 (UPN25), respectively. Informed consent to be included in this study was obtained according to the principles of the Declaration of Helsinki from patients or their parents.
Cytogenetic investigations were performed with routine methods. Patients' DNA was obtained from the same BM specimens used for chromosomal analysis; parental DNA was also available for all cases. DNA extraction was performed with GenElute Blood Genomic kit (Sigma, St Louis, MO, USA) and mutation analysis was performed as reported by Nicolis et al.
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We selected the short tandem repeat polymorphisms (STRPs) to be studied depending on their heterozygosity (always above 80%) and chromosomal mapping: D7S3048; D7S1808; D7S1818; D7S1830 (short arm) and D7S1820; D7S796; D7S2202; D7S1805 (long arm). Genotyping of STRPs was performed using ABI PRISM multicolour fluorescent dye technology based on labelling DNA fragments with different colour fluorescent dyes by PCR amplification. The PCR amplifications were performed as reported earlier. 9 The PCR products are displayed as electropherograms, showing fluorescence intensity as a function of fragment size or migration time. The GenScanView 1.2/4 software provides peak detection (areas and heights) relative to alleles amplified as DNA fragments. After the identification in each patient of the parental origin of the different STRPs tested, we compared the height of the paternal and maternal alleles and calculated the ratios between the allele coming from the parent carrying the c.258 þ 2T4C and that coming from his/her spouse, as this mutation is associated with the possibility of producing some amount of the wt protein. This method was applied to case nos 3-8, whereas case nos 1 and 2 were studied as reported by Maserati et al. 8, 9 RNA analysis was performed in case nos 4 and 6 as reported earlier. 7 
Results
Essential cytogenetic data are detailed in Table 1 . All patients showed the i(7)(q10) as the only anomaly in BM, with percentages of positive cells ranging from 20 to 100%.
The study of informative STRPs allowed us to determine the parental origin of the isochromosome. Table 2 shows the mean peak ratios of the STRP alleles derived from the parent carrying Follow-up in years (y) from SDS diagnosis. Table 2 Results of molecular analysis demonstrating the parental origin of the i (7) The number of STRP analysed is given in brackets.
c.258 þ 2T4C mutation in i(7)(q10) and risk of MDS/AML in SDS A Minelli et al the c.258 þ 2T4C mutation (indicated as B) and those of his/her spouse: the ratios for the short arm STRP alleles ranged from 0.47 to 0.80, whereas those for the long arm STRPs alleles ranged from 1.22 to 2.00. These results are in agreement with what we expected: as the i(7)(q10) includes two copies of the long arm and no copies of the short arm, a reduced amount of the SRTPs localized on the short arm and increased amounts of the long arms (as determined from the height of the peaks) should be found in the patients' BM, in relation to the parental origin of the chromosome 7 involved in the formation of the i(7)(q10). In case nos 1 and 2, the parental origin of the i(7)(q10), paternal and maternal, respectively, was determined earlier, 8, 9 and in both cases all the markers consistently showed that the abnormal chromosome carried the c.258 þ 2T4C alleles. As in other cases, the variations in peak height observed (Figure 1) consistently indicated that the i(7)(q10) originated from the parent carrying the mutation c.258 þ 2T4C, the mother in case no. 3, and the father in case nos 4-8. Thus, the i(7)(q10) originated from the parent carrying the c.258 þ 2T4C allele in all the eight cases studied. The SBDS wt-mRNA level was investigated in case nos 4 and 6 and expressed as (wt/wt þ mutated) peak height ratio; the ratio observed, 0.25 for case no. 4 and 0.20 for case no. 6, indicates that wt SBDS mRNA is present in both patients, at a level decreased by about 80% with respect to healthy controls (data not shown). The strength of the normal, mutated and cryptic splicing sites was determined by the Analyzer Splice Tools software (http://ast.bioinfo.tau.ac.il/SpliceSiteFrame.htm) and the results for splice sites score/number of base pairs/DG were as follows: normal site 84.90/9/-9; mutated site 67.0/7/-5.3 and cryptic site 68.40/5/-2.6.
Discussion
SDS is a complex disorder caused by mutations of the SBDS gene, in which MDS/AML may develop in a variable number of patients, 14-30%. 1, 12 No clear-cut correlation between certain cytogenetic anomalies found in BM (as well as specific mutations of the SBDS gene) and evolution into MDS/AML of SDS patients has been recognized in the literature. 1, 13 The role of cytogenetic abnormalities for MDS/AML development in SDS patients is still under debate. The most frequent chromosomal anomaly found in BM of SDS patients is the i(7)(q10), which from literature data may account up to 44% of the cases with anomalies; other anomalies involving chromosome 7 (monosomy, deletions and translocations) account for a further 33%, whereas the del(20)(q11) is found in around 16% of patients. 1 Although in patients without SDS affected by myeloid malignancies the del(20)(q11) and anomalies of chromosome 7 are frequent, 14 the i(7)(q10) was reported in a limited number of patients, such as a case with a transient picture suggestive of MDS, 15 a Down syndrome patient with AML 16 and few other MDS and AML cases. 14, 17 Therefore, the i(7)(q10) may be considered a fairly specific marker of SDS.
Alter 12 reviewed 510 reported SDS cases, and, it is noteworthy, no patient carrying the i(7)(q10) had developed MDS/AML, whereas in patients with overt evolution into MDS/ AML, other chromosome changes, including complex karyotypes, were observed. The difference as to the risk of MDS/AML between SDS cases with the i(7)(q10) and those with other acquired chromosome changes has been recently emphasized up to the point that haematopoietic stem cell transplantation is no longer considered indicated in patients with the i(7)(q10). 18 However, some exceptions to the rule that SDS patients with i(7)(q10) do not develop MDS/AML may exist, as suggested by two old reports of patients carrying this cytogenetic abnormality who developed refractory anaemia. 19, 20 The c.258 þ 2T4C mutation modifies the usual splice site at the donor site of intron 2 and, in turn, a cryptic splice site present at position 251-252 in exon 2 becomes active, resulting in an 8-bp deletion in mRNA sequence, which also causes a premature truncation of the encoded protein by frameshift (p.84Cfs3). 2 However, the c.258 þ 2T4C mutation, either in homozygous condition or in association with a rare mutation such as c.505C4T (p.R169C), still allows the production of some amount of normal protein. 6 This observation was recently confirmed by Nicolis et al. 7 who demonstrated the presence of some amount of normal mRNA in patients carrying the c.258 þ 2T4C mutation both as compound heterozygotes (258 þ 2T4C/183_184TA4CT) and as homozygotes (258 þ 2T4C/258 þ 2T4C). In fact, when the strength of the mutated and cryptic splice sites is compared, the scores obtained support the available evidence that the mutated splice site might be partially active. c.258 þ 2T4C mutation in i(7)(q10) and risk of MDS/AML in SDS A Minelli et al
As the SBDS gene is located on 7q11, BM cells with the i(7)(q10) have three copies of the gene, and we demonstrated that in all the eight cases studied the i(7)(q10) carries two copies of the c.258 þ 2T4C mutation (258-iso7).
We did not find any i(7)(q10) carrying the c.183_184TA4CT mutation, and no evidence leads to postulate that the c.258 þ 2T4C (and not the c.183_184TA4CT) might induce the formation of the i(7)(q10). A possible interpretation is that a cell with the genotype (258 þ 2T4C/258 þ 2T4 C/183_184TA4CT) may have a selective advantage over a cell with a possible genotype (183_184TA4CT/183_184TA4CT/ 258 þ 2T4C) as it may have a still small but larger amount of the wt protein. Therefore, only clones carrying the genotype (258 þ 2T4C/258 þ 2T4C/183_184TA4CT) would survive and would become identifiable.
Austin et al. 5 demonstrated that the SBDS protein stabilizes the mitotic spindle preventing genomic instability; this observation may suggest that cells with the 258-iso7 are less prone to develop additional chromosome abnormalities, which in turn may lead to MDS/AML, in keeping with the observation reviewed above that the i(7)(q10) was rarely seen in SDS patients with MDS/AML.
Our results provide the explanation for a biological advantage of BM cells with 258-iso7 (with respect to cells with other chromosome changes), and a convincing biological basis for the clinical observation of a reduced risk of developing MDS/AML in these SDS patients, which is of course relevant for their clinical follow-up and management.
